Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce mortality in left heart failure. In pre-capillary pulmonary hypertension (PH), preclinical data suggest SGLT2i may improve right ventricular (RV) function through metabolic modulation, reduced perivascular inflammation, and inhibition of vascular remodelin...
M. Ersbøll, J. Kjaergaard, F. Gustafsson et al.· European Heart Journal· 0 citations
Abstract Introduction Five-year survival after continuous-flow left ventricular assist device (LVAD) implantation has improved substantially, resulting in a growing population of ultra-long-term LVAD patients, defined as 5 years and longer survival on LVAD. Remarkably, determinants of mortality beyond the 5-year landma...
C. Velásquez-Silva, W. H. Nielsen, C. Møller et al.· ESC Heart Failure· 0 citations
This randomized study of SGLT2i in pre-capillary PH showed that 12 weeks of dapagliflozin did not significantly improve exercise capacity, hemodynamics, or functional status compared to placebo.
M. Ersbøll, J. Kjaergaard, K. Waidtløw et al.· The Journal of Heart and Lun...· 1 citation
Abstract Introduction Ambulatory low cardiac output state (LCOS) is a known but poorly described heart failure (HF) phenotype. We aimed to investigate the prevalence, clinical markers, and prognostic importance of ambulatory LCOS. Methods Consecutive ambulatory patients with HF and reduced left ventricular ejection fra...
B. Hansen, T. Deis, Cecilie Müller Ralsted et al.· ESC Heart Failure· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.